hotspot -WSS

hotspot

author：explore 2025-08-19 12:14:57 - browse：474

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

WSS

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Readers respond to H5N1 and livestock movements, and more

A new House health package & hospitals’ new site

Case highlights the risks of experimental stem cell therapy

Wearables generate powerful data but its not useful to doctors, yet

Criminal prosecution for violating HIPAA: an emerging threat

hotspot

hotspot

leisure time

Jerome Adams on the need for new antivirals for Covid

Ethical issues complicate the benefits of medical crowdfunding

Jerome Adams on the need for new antivirals for Covid

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Novavax promises a turnaround & Lilly roils the obesity market

NVIDIA and Google execs on the future of AI and drug discovery

ChatGPT in medicine: STAT answers readers' burning questions

Solving academic medical centers' existential crisis

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ALS advocates say criticism of new drugs misses bigger picture

focus

Crinetics acromegaly drug succeeds in late

Criminal prosecution for violating HIPAA: an emerging threat

Readers respond to H5N1 and livestock movements, and more

Big Tobacco's 'harm reduction': Is it for real, or a sham?

NIH nominee Bertagnolli will get October confirmation hearing

Readers respond to H5N1 and livestock movements, and more

leisure time

hotspot

entertainment

hotspot